OVARIAN CANCER and US: north american breast cancer group

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Showing posts with label north american breast cancer group. Show all posts
Showing posts with label north american breast cancer group. Show all posts

Sunday, February 12, 2012

abstract: Age-Specific Incidence Rates for Breast Cancer in Carriers of BRCA1 Mutations from Norway (compared to Poland/North America)



Clin Genet. 2012 Feb 9. doi: 10.1111/j.1399-0004.2012.01855.x. [Epub ahead of print]

"Incidence rates of breast cancer among women with a BRCA1 mutation vary according to their reproductive histories and country of residence. To measure cancer incidence, it is best to follow cohort of healthy women prospectively. We followed a cohort of 675 women with a BRCA1 mutation who had not had breast or ovarian cancer prior to inclusion and who had a normal clinical examination and mammography at first visit. After a mean of 7.1 years, 98 incident cases of breast cancer were recorded in the cohort. Annual cancer incidence rates were calculated, and based on these, a penetrance curve was constructed. The average annual cancer risk for the Norwegian women from age 25 to 70 was 2.0%. Founder mutations had lower incidence rate (1.7%) than less frequent mutations (2.5%) (p=0.03). The peak incidence (3.1% annual risk) was observed in women from age 50 to 59. The age-specific annual incidence rates and penetrance estimate were compared with published figures for women from North America and from Poland. The risk of breast cancer to age 70 was estimated to be 61% for women from Norway, compared to 55% for women from Poland and 69% for women from North America. (of those BRCA1)"

Friday, April 16, 2010

Multidisciplinary Meeting on Male Breast Cancer: Summary and Research Recommendations -- JCO



"Therefore, the Breast International Group and North American Breast Cancer Group have joined efforts to develop an International Male Breast Cancer Program and to pool epidemiologic data, clinical information, and tumor specimens. This international collaboration will also facilitate the future planning of clinical trials that can address essential questions in the treatment of male breast cancer."